Former FDA Commissioner Scott Gottlieb Joins Pfizer Board
Pfizer has announced the election of Scott Gottlieb, MD, the former US Food and Drug Administration (FDA) Commissioner, to its Board of Directors, effective with its announcement on June 27, 2019. Dr. Gottlieb was also appointed to the Regulatory and Compliance Committee and the Science and Technology Committee of Pfizer’s Board.
Dr. Gottlieb, a physician and medical policy expert, is currently a Special Partner of New Enterprise Associations’ (NEA) healthcare investment team and a Resident Fellow of the American Enterprise Institute, an economic research organization. NEA is a venture-capital firm. From 2017 to 2019, Dr. Gottlieb served as the 23rd Commissioner of the FDA.
Prior to serving as FDA Commissioner, Dr. Gottlieb held several roles in the public and private sectors, including serving as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped implement the Medicare drug benefit, advanced policies to improve healthcare quality, and promoted the effective use of new medical technologies. Dr. Gottlieb is also an elected member of the National Academy of Medicine.